What is William Blair’s Forecast for IONS FY2025 Earnings?

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) – Investment analysts at William Blair boosted their FY2025 earnings estimates for shares of Ionis Pharmaceuticals in a report issued on Tuesday, January 21st. William Blair analyst M. Minter now forecasts that the company will earn ($3.60) per share for the year, up from their prior estimate of ($3.80). William Blair has a “Outperform” rating on the stock. The consensus estimate for Ionis Pharmaceuticals’ current full-year earnings is ($3.47) per share.

IONS has been the subject of several other research reports. Wells Fargo & Company dropped their target price on shares of Ionis Pharmaceuticals from $82.00 to $77.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. Royal Bank of Canada restated an “outperform” rating and set a $70.00 target price on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. Guggenheim lowered their price target on Ionis Pharmaceuticals from $70.00 to $65.00 and set a “buy” rating for the company in a research note on Wednesday, October 9th. Finally, Piper Sandler reduced their price objective on shares of Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a research note on Thursday, November 14th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $60.65.

Ionis Pharmaceuticals Trading Up 0.8 %

IONS opened at $34.75 on Thursday. The firm has a 50 day simple moving average of $35.23 and a 200 day simple moving average of $40.72. Ionis Pharmaceuticals has a fifty-two week low of $31.40 and a fifty-two week high of $52.49. The company has a market cap of $5.49 billion, a price-to-earnings ratio of -14.24 and a beta of 0.35. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, Director Michael R. Hayden bought 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 23rd. The stock was acquired at an average price of $36.22 per share, with a total value of $181,100.00. Following the completion of the transaction, the director now owns 35,219 shares in the company, valued at approximately $1,275,632.18. This trade represents a 16.55 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Eric Swayze sold 1,194 shares of the business’s stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $37.92, for a total transaction of $45,276.48. Following the sale, the executive vice president now directly owns 33,713 shares in the company, valued at $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 57,293 shares of company stock worth $1,914,820. 2.71% of the stock is owned by corporate insiders.

Institutional Trading of Ionis Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the stock. Amalgamated Bank increased its position in shares of Ionis Pharmaceuticals by 4.9% during the 2nd quarter. Amalgamated Bank now owns 9,657 shares of the company’s stock worth $460,000 after purchasing an additional 454 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its holdings in Ionis Pharmaceuticals by 3.5% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 7,624 shares of the company’s stock worth $363,000 after buying an additional 261 shares during the last quarter. Hsbc Holdings PLC bought a new stake in Ionis Pharmaceuticals during the second quarter worth $252,000. Ensign Peak Advisors Inc lifted its stake in Ionis Pharmaceuticals by 28.0% in the second quarter. Ensign Peak Advisors Inc now owns 68,270 shares of the company’s stock valued at $3,254,000 after acquiring an additional 14,950 shares during the last quarter. Finally, Xponance Inc. grew its position in shares of Ionis Pharmaceuticals by 11.8% in the 2nd quarter. Xponance Inc. now owns 18,115 shares of the company’s stock valued at $863,000 after acquiring an additional 1,906 shares during the period. Institutional investors and hedge funds own 93.86% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.